仁度生物(688193.SH)：预计2025年归母净利润为720万元到1080万元，将实现扭亏为盈

Core Viewpoint - Rendu Biotech (688193.SH) is expected to achieve a net profit attributable to the parent company of between 7.20 million and 10.80 million yuan in 2025, marking a significant turnaround from a loss in the previous year [1] Financial Performance - The projected net profit for 2025 represents an increase of 15.01 million to 18.61 million yuan compared to the previous year's statutory disclosure data, indicating a return to profitability [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -14.50 million and -11.00 million yuan, which is an improvement of 5.06 million to 8.56 million yuan from the previous year [1] Operational Improvements - The primary reasons for the performance changes include the implementation of the "Quality Improvement and Efficiency Enhancement" action plan, which has led to cost reduction and efficiency improvements [1] - The company has strengthened its accounts receivable management, recovering some receivables from previous years, and has reversed some impairment losses in accordance with accounting standards and company policies [1]